Common questions about PBMC isolation, stimulation, cryopreservation, and cytokine measurement using Luminex multiplex technology.
Should I use heparin or EDTA for PBMC blood collection?
Heparin is strongly recommended if your study includes PMA/ionomycin stimulation. Ionomycin is a calcium ionophore and requires extracellular Ca²+ to function; EDTA chelates calcium and will abolish ionomycin activity. For anti-CD3/CD28 stimulation without ionomycin, either heparin or EDTA is acceptable. If you have already collected EDTA samples, the isolated PBMCs can be used after thorough washing (2–3 times) in calcium-containing medium. For new studies, use heparin tubes (green cap) as the standard.
Can I ship cryopreserved PBMCs instead of fresh cells?
Yes. Cryopreserved PBMCs shipped on dry ice are the recommended format for multi-site studies and batch analysis. Cryopreserved PBMCs typically produce 50–80% of the cytokine output of fresh PBMCs upon stimulation. Th1 cytokines (IFN-γ, TNF-α) are better preserved than Th2 cytokines (IL-4, IL-5). All samples in a study must be either all fresh or all cryopreserved — never mix fresh and frozen PBMCs in the same analysis.
Do I need to include an unstimulated control for each donor?
Yes, absolutely. The unstimulated control is essential for interpreting stimulated cytokine data. It provides the baseline secretion level for each donor, from which the stimulation fold-change is calculated. Without an unstimulated control, you cannot distinguish true stimulation responses from elevated basal secretion (e.g., due to in vivo immune activation). We require an unstimulated control for every donor included in a stimulated PBMC study. The unstimulated control should be cultured in parallel under identical conditions, with medium only (no stimulant).
How many PBMCs do I need per condition?
For unfractionated PBMCs, 0.5–2 × 10&sup6; cells per condition in 200–500 μL medium is standard. For purified cell subsets (CD4+, CD8+, NK cells), 0.1–0.5 × 10&sup6; cells per condition. A typical 10 mL heparin tube yields 10–20 × 10&sup6; PBMCs, sufficient for 5–10 stimulation conditions plus unstimulated control. For multi-panel studies (e.g., cytokine + chemokine + checkpoint panels from the same supernatant), 25 μL of supernatant per panel is required.
How long should I stimulate PBMCs before collecting supernatant?
For PMA/ionomycin: 3–6 hours for peak cytokine detection. Longer stimulation (18–24 hours) may be used for exhaustion markers but cell viability declines. For anti-CD3/CD28: 24–48 hours; shorter stimulation produces suboptimal cytokine output for most analytes except IFN-γ. For unstimulated controls: match the incubation time of your stimulated condition exactly.
What viability is acceptable for PBMC cytokine assays?
Freshly isolated PBMCs should have >90% viability by trypan blue exclusion. Post-thaw viability should be >80% after the 1–2 hour resting period. PBMCs with viability <80% produce unreliable cytokine data because dead and dying cells release intracellular contents that interfere with the immunoassay and may activate remaining live cells through DAMPs (damage-associated molecular patterns). We assess viability upon receipt and will notify you if samples fall below acceptable thresholds.
How are values below the detection limit reported for PBMC supernatants?
Concentrations below LLOD are flagged. For unstimulated PBMCs, many cytokines (IL-2, IL-4, IL-17A) may be below LLOD in healthy donors — this is expected and not a technical failure. These same cytokines should become detectable upon stimulation. If stimulated samples also fall below LLOD, this may indicate a stimulation failure or genuine immune deficiency. We include a positive control (PMA/ionomycin-stimulated healthy donor PBMCs) on each plate to verify stimulation efficiency.
What is the minimum project size for PBMC Luminex assays?
One 96-well plate. For PBMC studies, this typically accommodates 10–15 donors × 2 conditions (unstimulated + stimulated) in duplicate, plus standards and QC. For larger cohorts, samples can be distributed across multiple plates with a bridge control sample to normalize inter-plate variability.
